Clinical Trial Update: Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating intravenous Trappsol Cyclo (HPBCD) for Niemann-Pick disease type C1, focusing on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Niemann-pick Disease Type

Drugs mentioned

• Trappsol Cyclo (Hydroxypropyl-β-cyclodextrin)

Snippet

Sponsor: Cyclo Therapeutics, Inc. | Conditions: Niemann-Pick Disease, Type C1 | Phase 1, Phase 2 | Status: COMPLETED